article thumbnail

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders

Pharmaceutical Technology

We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.” Hangzhou Highlightll will also receive up to $950m in development and commercial milestone payments and tiered royalties.

Licensing 263
article thumbnail

3BP and Novartis strike licensing agreement for FAP-targeting peptide technology

Pharmaceutical Technology

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BREAKING: Breast cancer drug licensed as preventative measure

Outsourcing Pharma

A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.

Licensing 111
article thumbnail

Sosei to regain rights to IBD drug after GSK discontinues programme

Pharmaceutical Technology

The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.

Licensing 147
article thumbnail

Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug

BioSpace

Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.

Licensing 102
article thumbnail

Roche licenses drug to target cancer DNA damage response

Outsourcing Pharma

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 93
article thumbnail

Vaderis exits stealth as ex-Almac Discovery candidate enters clinical development

Outsourcing Pharma

The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company.